Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? PetVivo’s new study shows that a single intra-articular Spryng injection with OsteoCushion technology can improve pain and function in dogs with stifle osteoarthritis and suspected cranial cruciate disease. While the authors call for larger studies with obj...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
Quick Takeaways: Why It Matters? ALA-1000’s data support a true once-monthly, long-acting analgesic option, which could meaningfully shift osteoarthritis pain management away from daily oral medications in suitable dogs. If approved, the combination of dura...
Quick Takeaways: Why It Matters? Data for LPT‑CBD strengthens the scientific case for long‑acting, injectable CBD as a legitimate chronic pain option, not just a wellness supplement, which can increase veterinarian openness to cannabinoid-based therapies. The sustaine...
